Overview
IQVIA Holdings Inc. provides clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its work combines health data, analytics, technology and industry expertise.[1] The company reports two core segments: Commercial Solutions, covering information, analytics, technology and related healthcare services; and Research & Development Solutions, covering outsourced clinical research, clinical trials and real-world research.[2]
IQVIA operates internationally, with approximately 93,000 employees and clients in more than 100 countries, and reports activity across the Americas, Europe and Africa, and Asia-Pacific.[1][3][4] Revenue was $16.310 billion in fiscal 2025.[5] The company describes its mission as “accelerating innovation for a healthier world.” [6] [1][2][3][4][5][6]
Products & services
IQVIA’s commercial data, software and analytics offerings include cloud applications for customer relationship management, performance management, real-world evidence, safety and compliance reporting, incentive compensation, territory alignment, call planning, multichannel marketing and master-data management. Named market-insight products include MIDAS, Analytics Link and Disease Insights. Its information products provide national market metrics in more than 100 countries, subnational measures in more than 70 countries, and reference data on over 22 million healthcare professionals across more than 100 countries.[7][8][9] IQVIA describes OCE as a platform for coordinated personal and digital commercial engagement, OCE+ as adding Next Best recommendations and AI decision support, OneKey as HCP reference and targeting data, and Analytics Link Ecosystem as connecting commercial, patient, pipeline, trial, launch, patent and deal information.[10][11][12][13]
Its real-world evidence and healthcare-data capabilities include more than 1.2 billion longitudinal, unique non-identified patient records and approximately 68 petabytes of proprietary data sourced from about 150,000 suppliers and over one million feeds. Data types include sales, prescription, promotional, social-media, claims, electronic health records and genomics; IQVIA describes capabilities for data standardization, curation, integration, analytics and privacy-compliant tokenization. Its Health Data Catalog profiles more than 4,600 real-world data assets in over 100 countries, and natural-language processing is used to structure information from clinical notes and literature.[14][15]
Research and development services support Phase I–IV trials, including protocol design, feasibility, site start-up, patient recruitment and monitoring; functional trial support; clinical, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratories; and regulatory, biostatistics, modeling and simulation, and benefit-risk consulting. The company also provides decentralized-trial services such as direct-to-patient recruitment, remote nursing and study coordination, and names the Avacare Clinical Research Network among its offerings.[16][17][18][19][20] Other services include contract sales and market-access personnel, nurse-led patient education and adherence support, reimbursement navigation, and medical-affairs services such as scientific strategy, clinical-site education, publication planning and field medical teams.[21][22][23]
IQVIA reports revenue by segment rather than by individual product or service. In FY2025, Technology & Analytics Solutions generated $6.626 billion (40.6% of total revenue), Research & Development Solutions $8.896 billion (54.5%), and Contract Sales & Medical Solutions $0.788 billion (4.8%), out of $16.310 billion total.[24][24][24][24] In the first half of 2026, under a recast segment structure, Commercial Solutions generated $3.547 billion (41.6%) and Research & Development Solutions $4.972 billion (58.4%), out of $8.519 billion total. The 2026 categories are not directly comparable with FY2025: Contract Sales & Medical was incorporated into Commercial Solutions, while certain real-world offerings moved to Research & Development Solutions.[25][26][26][26] [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][24][24][24][25][26][26][26][10][11][12][13]
Geographic presence
IQVIA reports revenue by the region where services are performed, grouping its business into the Americas, Europe and Africa, and Asia-Pacific. For FY2025, revenue was $7.745 billion in the Americas (47.5% of total), $5.185 billion in Europe and Africa (31.8%), and $3.380 billion in Asia-Pacific (20.7%), out of $16.310 billion. Percentages are calculated from the reported regional revenue amounts.[27][28]
At year-end 2025, IQVIA had 304 offices and laboratories in 87 countries, with its executive headquarters in Research Triangle Park, North Carolina. Its owned facilities included locations in Buenos Aires, Argentina; Caracas and Los Ruices, Venezuela; and Bangalore, India; other offices were leased. The company reported approximately 93,000 employees worldwide, but did not disclose their distribution by geography.[29][30] [27][28][28][28][28][29][30]
Business segments
For the year ended December 31, 2025, IQVIA reported three operating segments. Technology & Analytics Solutions provides information, technology solutions, real-world insights and related services to life-sciences clients; its revenue was $6.626 billion, approximately 40.6% of company revenue.[31][5] Research & Development Solutions primarily serves biopharma clients with outsourced clinical research and clinical-trial-related services; revenue was $8.896 billion, approximately 54.5%.[31][5] Contract Sales & Medical Solutions provides services to healthcare providers, including contract sales, and patient-engagement services for biopharma and the broader healthcare market; revenue was $788 million, approximately 4.8%.[31][5] Total revenue was $16.310 billion.[5]
The company also presents revenue by geographic region, separately from its three reportable operating segments.[28] Effective January 1, 2026, it planned to fold Contract Sales & Medical Solutions into Technology & Analytics Solutions, to be renamed Commercial Solutions, and transfer certain real-world offerings to Research & Development Solutions; recast segment information was to begin with the first-quarter 2026 filing.[32] [31][5][5][5][5][28][32][33]
Company history
IQVIA’s predecessor businesses began as distinct companies: IMS Health traces its origins to 1954, while Quintiles was founded in 1982 by Dennis Gillings. Their roots were in healthcare information and analytics, and clinical research, respectively.[34][35] In 2014, IMS Health agreed to acquire Cegedim’s information-solutions and CRM businesses; the acquisition was completed in 2015.[36]
IMS Health and Quintiles announced an all-stock merger in May 2016, and completed the combination on October 3, 2016, as Quintiles IMS Holdings. Ari Bousbib became chairman and CEO following the merger.[37][38][39] In November 2017, the company adopted the name IQVIA, reflecting the combination of its predecessor businesses.[40] In April 2021, IQVIA acquired Quest Diagnostics’ remaining 40% interest in Q² Solutions, making the clinical-laboratory business wholly owned.[41] [39][34][35][36][37][38][40][41]
Sources
- IQVIA HOLDINGS INC. — Full financial report (2025 Y)
- IQVIA HOLDINGS INC. — Full financial report (2026 Q 2)
- test-www.iqvia.com[10]
- www.iqvia.com[11]
- www.iqvia.com[12]
- www.iqvia.com[13]
- www.sec.gov[33]
- jobs.iqvia.com[34]
- www.sec.gov[35]
- ir.iqvia.com[36]
- ir.iqvia.com[37]
- www.iqvia.com[38]
- www.iqvia.com[40]
- www.iqvia.com[41]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore IQVIA HOLDINGS INC. in Finbar ↗